STX-1150, a liver-targeted CRISPR-based epigenetic therapy, achieved up to 68% LDL-C reduction from a single dose in non-human primates, with effects sustained beyond 22 months. The approach modulates gene expression without permanent DNA alteration, advancing toward human trials with regulatory clearance in Australia.
Key Points
- Single dose produced 68% LDL-C reduction sustained 22+ months
- PCSK9 reductions reached 90% with five-fold greater potency in human hepatocytes
- No off-target gene changes or liver toxicity detected in preclinical assessment
Longevity Analysis
Epigenetic silencing of PCSK9 represents a departure from permanent genetic modification toward reversible cellular reprogramming. By targeting the liver's cholesterol metabolism without altering DNA sequence, this approach addresses a core cardiovascular risk factor through a single intervention with durability. The sustained response across two decades in animal models suggests potential for reducing the treatment burden associated with chronic lipid management, while the absence of off-target effects indicates a refined capacity to intervene at the transcriptional level. This method exemplifies how precise epigenetic control could reduce interference from elevated cholesterol while improving the body's ability to maintain healthy lipoprotein profiles through altered cellular signaling rather than permanent genetic change.
Original published by LT Wire.